Defining the role of TORC1/2 in multiple myeloma
- 22 December 2011
- journal article
- Published by American Society of Hematology in Blood
- Vol. 118 (26), 6860-6870
- https://doi.org/10.1182/blood-2011-03-342394
Abstract
Mammalian target of rapamycin (mTOR) is a downstream serine/threonine kinase of the PI3K/Akt pathway that integrates signals from the tumor microenvironment to regulate multiple cellular processes. Rapamycin and its analogs have not shown significant activity in multiple myeloma (MM), likely because of the lack of inhibition of TORC2. In the present study, we investigated the baseline activity of the PI3K/Akt/mTOR pathway TORC1/2 in MM cell lines with different genetic abnormalities. TORC1/2 knock-down led to significant inhibition of the proliferation of MM cells, even in the presence of BM stromal cells. We also tested INK128, a dual TORC1/2 inhibitor, as a new therapeutic agent against these MM cell lines. We showed that dual TORC1/2 inhibition is much more active than TORC1 inhibition alone (rapamycin), even in the presence of cytokines or stromal cells. In vitro and in vivo studies showed that p-4EBP1 and p-Akt inhibition could be predictive markers of TORC2 inhibition in MM cell lines. Dual TORC1/2 inhibition showed better inhibition of adhesion to BM microenvironmental cells and inhibition of homing in vivo. These studies form the basis for further clinical testing of TORC1/2 inhibitors in MM.This publication has 35 references indexed in Scilit:
- Constitutive reductions in mTOR alter cell size, immune cell development, and antibody productionBlood, 2011
- Dissecting the role of mTOR: Lessons from mTOR inhibitorsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- The Magnitude of Akt/Phosphatidylinositol 3′-Kinase Proliferating Signaling Is Related to CD45 Expression in Human Myeloma CellsThe Journal of Immunology, 2004
- Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progressionOncogene, 2004
- Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasoneBlood, 2004
- Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM modelBritish Journal of Cancer, 2004
- Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathwayOncogene, 2003
- Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle ProgressionCell Cycle, 2003
- Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.2002
- PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cellsOncogene, 2002